摘要
静脉血栓栓塞症疾病的发生,临床上表现为恶性肿瘤的并发症,产生后,表现为深静脉血栓和肺动脉栓塞等疾病。为了对该疾病积极预防,利伐沙班口服使用简便、剂量固定、无需凝血功能监测、受食物药物影响小、不依赖AT-Ⅲ起效等优势,临床应用更加简便,患者更容易接受,有待成为恶性肿瘤相关性静脉血栓栓塞预防工作的新星。
The occurrence of venous thromboembolic disease is clinically a complication of malignant tumors. After the occurrence, it is characterized by deep vein thrombosis and pulmonary embolism. In order to actively prevent the disease, rivaroxaban is easy to use, convenient in dosage, no need to monitor blood coagulation, less affected by food or drugs, and does not rely on the effect of AT-Ⅲ. The clinical application is more conve-nient and the patient is more acceptable. Rivaroxaban becomes a new star in the prevention of malignant tumor-related venous thromboembolism.
作者
何剑波
甘海洁
曾爱屏
He Jianbo;Gan Haijie;Zeng Aiping(Department of Respiratory Oncology, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi, 530021, China)
出处
《当代医学》
2019年第7期183-186,共4页
Contemporary Medicine
基金
广西医疗卫生适宜技术开发与推广应用项目(S201630)
关键词
恶性肿瘤
相关性
血管栓塞
预防
利伐沙班
Malignant tumor
Relevance
Vascular embolization
Prevention
Rivaroxaban
